We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) announced that it has initiated a new mid-stage study that will evaluate its pipeline candidate, rezpegaldesleukin (rezpeg), for treating patients with severe to very severe alopecia areata, an autoimmune disorder characterized by patchy hair loss.
Alopecia areata is a condition affecting nearly 700,000 of the American population currently. The disease has a tremendous adverse impact on the quality of life of the patients.
The double-blind, placebo-controlled, global phase IIb study will evaluate the safety and efficacy of rezpeg in patients with severe to very severe alopecia areata over a period of 36-week induction treatment. The study will compare two different dosing regimens of rezpeg versus placebo in 84 participants during the induction period.
The primary efficacy endpoint of the study is the mean percent improvement in the Severity of Alopecia Tool (SALT) at week 36 of treatment.
Shares of Nektar have plunged 33.5% in the past year compared with the industry’s decline of 2.4%.
Image Source: Zacks Investment Research
Nektar is also developing rezpeg for various other types of autoimmune and inflammatory diseases.
A phase IIb study is evaluating rezpeg in biologic-naïve patients with moderate-to-severe atopic dermatitis, also called eczema. Initial data from this study is expected in the first half of 2025.
It is to be noted that NKTR regained full rights to rezpeg from Eli Lily (LLY - Free Report) in April 2023, and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with LLY for several autoimmune indications. It is now a wholly owned asset of Nektar and the company does not owe any further royalty payment to Lilly.
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 12.9%.
Indivior’s earnings beat estimates in each of the trailing three quarters, delivering an average surprise of 48.06%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, shares of VNDA have plunged 34.1%.
Vanda Pharmaceuticals’ earnings beat estimates in each of the trailing three quarters, delivering an average surprise of92.88%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Nektar Therapeutics (NKTR - Free Report) announced that it has initiated a new mid-stage study that will evaluate its pipeline candidate, rezpegaldesleukin (rezpeg), for treating patients with severe to very severe alopecia areata, an autoimmune disorder characterized by patchy hair loss.
Alopecia areata is a condition affecting nearly 700,000 of the American population currently. The disease has a tremendous adverse impact on the quality of life of the patients.
The double-blind, placebo-controlled, global phase IIb study will evaluate the safety and efficacy of rezpeg in patients with severe to very severe alopecia areata over a period of 36-week induction treatment. The study will compare two different dosing regimens of rezpeg versus placebo in 84 participants during the induction period.
The primary efficacy endpoint of the study is the mean percent improvement in the Severity of Alopecia Tool (SALT) at week 36 of treatment.
Shares of Nektar have plunged 33.5% in the past year compared with the industry’s decline of 2.4%.
Image Source: Zacks Investment Research
Nektar is also developing rezpeg for various other types of autoimmune and inflammatory diseases.
A phase IIb study is evaluating rezpeg in biologic-naïve patients with moderate-to-severe atopic dermatitis, also called eczema. Initial data from this study is expected in the first half of 2025.
It is to be noted that NKTR regained full rights to rezpeg from Eli Lily (LLY - Free Report) in April 2023, and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with LLY for several autoimmune indications. It is now a wholly owned asset of Nektar and the company does not owe any further royalty payment to Lilly.
Zacks Rank & Stocks to Consider
Nektar currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the healthcare sector are Indivior PLC (INDV - Free Report) and Vanda Pharmaceuticals Inc. (VNDA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 12.9%.
Indivior’s earnings beat estimates in each of the trailing three quarters, delivering an average surprise of 48.06%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, shares of VNDA have plunged 34.1%.
Vanda Pharmaceuticals’ earnings beat estimates in each of the trailing three quarters, delivering an average surprise of92.88%.